T淋巴细胞亚群水平对阿德福韦酯治疗慢性乙型肝炎疗效的影响  

T- lymphocyte subsets levels on the efficacy of adefovir in the treatment of patients with chronic hepatitis B

作　　者：蒋阳昆[1] 涂燕云[1] 许剑[2] 陈黎[1] 林海[1] 

机构地区：[1]广西中医学院附属瑞康医院肝胆内科,南宁市530011 [2]贵阳中医学院第二附属医院消化内科

出　　处：《实用肝脏病杂志》2010年第4期263-264,共2页Journal of Practical Hepatology

基　　金：广西中医学院自然科学基金资助项目(编号:2005040)

摘　　要：目的观察T淋巴细胞亚群变化对阿德福韦酯治疗CHB患者疗效的影响。方法根据治疗前T淋巴细胞亚群水平将42例CHB患者分为CD4+/CD8+细胞比值低水平组和高水平组,观察阿德福韦酯治疗12个月的疗效。结果治疗后两组患者ALT和AST水平下降,但高水平组下降更明显(P<0.05);治疗后两组患者血清HBVDNA水平分别为4.2±1.2copies/ml和4.5±1.5copies/m(lP>0.05);治疗后高水平组患者HBeAg阴转率为38.89%(7/18),低水平组为18.75%(3/16,P<0.05)。结论治疗前T淋巴细胞亚群水平较高的CHB患者在应用阿德福韦酯治疗后疗效较好。Objective To observe the efficacy of adefovir on patient with CHB. Method 42 CHB patients were divided into two groups based on the ratio of CD4^＋/CD8^＋. Two groups received adefovir for 12 months. Results After 12 months treatment,the high level group got a better improvement in the liver function,HBV DNA loss and HbeAg negative rate. Conclusion Pre-treatment levels of T lymphocyte subgroup in CHB will influence the efficacy of adefovir dipivoxil treatment.

关 键 词：慢性乙型肝炎 T淋巴细胞亚群 阿德福韦酯 疗效 

分 类 号：R512.62[医药卫生—内科学]